These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 27589525)

  • 21. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
    Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
    Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short- and Long-Term Functional Connectivity Differences Associated with Alzheimer's Disease Progression.
    Mondragón JD; Marapin R; De Deyn PP; Maurits N
    Dement Geriatr Cogn Dis Extra; 2021; 11(3):235-249. PubMed ID: 34721501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrospinal fluid growth-associated protein 43 levels in patients with progressive and stable mild cognitive impairment.
    Lu Y;
    Aging Clin Exp Res; 2022 Oct; 34(10):2399-2406. PubMed ID: 35988117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Effect of the APOE Genotype on Individual BrainAGE in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
    Löwe LC; Gaser C; Franke K;
    PLoS One; 2016; 11(7):e0157514. PubMed ID: 27410431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced resting-state functional connectivity between core memory-task activation peaks is associated with memory impairment in MCI.
    Zhang Y; Simon-Vermot L; Araque Caballero MÁ; Gesierich B; Taylor ANW; Duering M; Dichgans M; Ewers M;
    Neurobiol Aging; 2016 Sep; 45():43-49. PubMed ID: 27459924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apolipoprotein E epsilon 4 allele is associated with increased atrophy in progressive mild cognitive impairment: a voxel-based morphometric study.
    Hämäläinen A; Grau-Olivares M; Tervo S; Niskanen E; Pennanen C; Huuskonen J; Kivipelto M; Hänninen T; Tapiola M; Vanhanen M; Hallikainen M; Helkala EL; Nissinen A; Vanninen RL; Soininen H
    Neurodegener Dis; 2008; 5(3-4):186-9. PubMed ID: 18322386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abnormal Resting-State Functional Connectivity Strength in Mild Cognitive Impairment and Its Conversion to Alzheimer's Disease.
    Li Y; Wang X; Li Y; Sun Y; Sheng C; Li H; Li X; Yu Y; Chen G; Hu X; Jing B; Wang D; Li K; Jessen F; Xia M; Han Y
    Neural Plast; 2016; 2016():4680972. PubMed ID: 26843991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of pituitary adenylate cyclase-activating polypeptide with cognitive decline in mild cognitive impairment due to Alzheimer disease.
    Han P; Caselli RJ; Baxter L; Serrano G; Yin J; Beach TG; Reiman EM; Shi J
    JAMA Neurol; 2015 Mar; 72(3):333-9. PubMed ID: 25599520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
    Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
    J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Relationship between episodic memory and resting-state brain functional connectivity network in patients with Alzheimer's disease and mild cognition impairment].
    Wu QJ; Guo ZJ; Liu SE; Yu HQ; Chen J; Yang HM
    Zhonghua Yi Xue Za Zhi; 2013 Jun; 93(23):1795-800. PubMed ID: 24124712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of cerebrospinal fluid biomarkers to predict conversion to dementia in patients with mild cognitive impairment: a clinical cohort study.
    Tondelli M; Bedin R; Chiari A; Molinari MA; Bonifacio G; Lelli N; Trenti T; Nichelli P
    Clin Chem Lab Med; 2015 Feb; 53(3):453-60. PubMed ID: 25274948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring Structural and Functional Brain Changes in Mild Cognitive Impairment: A Whole Brain ALE Meta-Analysis for Multimodal MRI.
    Gu L; Zhang Z
    ACS Chem Neurosci; 2019 Jun; 10(6):2823-2829. PubMed ID: 30808171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreased Parietal Beta Power as a Sign of Disease Progression in Patients with Mild Cognitive Impairment.
    Musaeus CS; Nielsen MS; Østerbye NN; Høgh P
    J Alzheimers Dis; 2018; 65(2):475-487. PubMed ID: 30056426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abnormal Functional Brain Networks in Mild Cognitive Impairment and Alzheimer's Disease: A Minimum Spanning Tree Analysis.
    Wang B; Miao L; Niu Y; Cao R; Li D; Yan P; Guo H; Yan T; Wu J; Xiang J;
    J Alzheimers Dis; 2018; 65(4):1093-1107. PubMed ID: 30149457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers.
    Rhodius-Meester HF; Koikkalainen J; Mattila J; Teunissen CE; Barkhof F; Lemstra AW; Scheltens P; Lötjönen J; van der Flier WM
    J Alzheimers Dis; 2016; 50(1):261-70. PubMed ID: 26577521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discriminating Alzheimer's disease progression using a new hippocampal marker from T1-weighted MRI: The local surface roughness.
    Platero C; López ME; Carmen Tobar MD; Yus M; Maestu F
    Hum Brain Mapp; 2019 Apr; 40(5):1666-1676. PubMed ID: 30451343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha 1-antichymotrypsin may be a biomarker for the progression of amnestic mild cognitive impairment.
    Liu S; Pan J; Tang K; Lei Q; He L; Cai X; Li Z
    Acta Neurol Belg; 2021 Apr; 121(2):451-464. PubMed ID: 31494860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Three subsystems of the inferior parietal cortex are differently affected in mild cognitive impairment.
    Liang P; Wang Z; Yang Y; Li K
    J Alzheimers Dis; 2012; 30(3):475-87. PubMed ID: 22451310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.